Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 12, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug application to the U.S. Food and Drug...
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
May 11, 2022 09:30 ET
|
Entrada Therapeutics, Inc.
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second...
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 10, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of...
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
February 23, 2022 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
January 05, 2022 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
December 17, 2021 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
December 09, 2021 07:00 ET
|
Entrada Therapeutics, Inc.
Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company...
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
November 18, 2021 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Therapeutics Announces Closing of Initial Public Offering
November 02, 2021 16:26 ET
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™)...